MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-31-2025
Merus N.V. Total Shareholders Equity 2011-2025 | MRUS
Annual Total Shareholders Equity Merus N.V.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 648 M | 356 M | 247 M | 316 M | 102 M | 131 M | 106 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 648 M | 102 M | 272 M |
Quarterly Total Shareholders Equity Merus N.V.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 775 M | 842 M | 596 M | 648 M | 703 M | 747 M | 349 M | 356 M | 393 M | 257 M | 218 M | 247 M | 299 M | 327 M | 297 M | 316 M | 206 M | 219 M | 237 M | 102 M | 102 M | 102 M | 102 M | 131 M | 131 M | 131 M | 131 M | 106 M | - | - | - | 67.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 842 M | 67.9 M | 315 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aptorum Group Limited
APM
|
21.1 M | $ 1.3 | - | $ 7.09 M |  China |
 |
Arbutus Biopharma Corporation
ABUS
|
106 M | $ 5.01 | 6.26 % | $ 831 M |  Canada |
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
156 M | $ 3.26 | 0.31 % | $ 252 M |  USA |
 |
AlloVir
ALVR
|
113 M | - | 4.14 % | $ 49.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
4.76 M | $ 1.06 | -6.19 % | $ 293 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.44 M | $ 0.27 | -3.93 % | $ 588 M |  Israel |
 |
Catalyst Biosciences
CBIO
|
-15.8 M | $ 13.88 | -1.53 % | $ 914 M | USA |
 |
Ascendis Pharma A/S
ASND
|
884 M | $ 221.31 | 0.4 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
35.5 M | $ 3.18 | -2.93 % | $ 7.65 B |  Australia |
 |
Catalyst Pharmaceuticals
CPRX
|
728 M | $ 24.01 | 1.65 % | $ 2.84 B | USA |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M |  France |
 |
CorMedix
CRMD
|
70.1 M | $ 11.08 | -3.57 % | $ 564 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.93 B | $ 57.6 | 1.62 % | $ 4.86 B |  Schweiz |
 |
BioVie
BIVI
|
19 M | $ 1.39 | -4.03 % | $ 2.05 M | USA |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
39.5 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
1.37 B | $ 94.09 | -0.76 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
518 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
732 M | $ 26.23 | 3.8 % | $ 1.27 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
597 M | $ 10.87 | 0.65 % | $ 1.41 B | USA |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
212 M | $ 9.57 | 0.05 % | $ 140 M | USA |
 |
Eton Pharmaceuticals
ETON
|
15.5 M | $ 16.36 | -2.07 % | $ 420 M | USA |
 |
Exelixis
EXEL
|
2.24 B | $ 41.5 | 1.5 % | $ 12 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
673 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
16.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.8 M | - | -52.27 % | $ 4.45 M | USA |
|
Foghorn Therapeutics
FHTX
|
-45.5 M | $ 4.48 | 0.82 % | $ 246 M | USA |
 |
AVROBIO
AVRO
|
94.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
2.33 B | $ 551.02 | -2.35 % | $ 41.7 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
19 M | $ 2.37 | 3.04 % | $ 14.9 M | USA |
 |
AstraZeneca PLC
AZN
|
15.6 B | $ 91.14 | 1.46 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
9.93 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
1.7 B | $ 8.88 | -1.33 % | $ 1.46 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
3.33 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-739 M | $ 11.43 | -0.87 % | $ 739 M | USA |
 |
Biogen
BIIB
|
16.7 B | $ 173.99 | -0.06 % | $ 25.3 B | USA |
 |
Abeona Therapeutics
ABEO
|
14.8 M | $ 5.13 | -4.38 % | $ 110 M | USA |